Comparative Pharmacology
Head-to-head clinical analysis: DUOPA versus RYTARY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUOPA versus RYTARY.
DUOPA vs RYTARY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUOPA is a combination of carbidopa and levodopa. Levodopa is a precursor of dopamine that crosses the blood-brain barrier and is converted to dopamine in the brain, replenishing depleted dopamine stores in the striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing the availability of levodopa for transport to the brain.
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain, thereby increasing dopamine levels in the substantia nigra and striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, reducing peripheral side effects and increasing levodopa availability to the brain.
One capsule orally, once daily at bedtime. Dose strengths available: 23.75 mg/9.5 mg (carbidopa/levodopa), 36.25 mg/14.5 mg, 48.75 mg/19.5 mg, 61.25 mg/24.5 mg. Titrate based on efficacy and tolerability; maximum dose 61.25 mg/24.5 mg.
Initial: 23.75 mg/95 mg orally three times daily for 3 days, then increase to 36.25 mg/145 mg three times daily. Titrate based on response and tolerability. Maximum dose: 97.5 mg/390 mg three times daily.
None Documented
None Documented
Levodopa 1-2 h; carbidopa 1-2 h; clinical context: short t1/2 requires frequent dosing; extended-release formulation prolongs
Carbidopa: 2-3 hours; Levodopa: 1-2 hours (immediate-release component), levodopa elimination half-life extended to approximately 5-6 hours for the extended-release component; clinical context: allows once-daily dosing despite short half-life of IR component due to ER formulation
Renal: carbidopa ~50% unchanged, levodopa minimal; fecal: ~30% of levodopa metabolites; biliary: minor
Renal (approximately 80% as metabolites, including 3-O-methyldopa and other conjugates; <1% unchanged); biliary/fecal (approximately 10-15%)
Category C
Category C
Decarboxylase Inhibitor/Dopamine Precursor Combination
Decarboxylase Inhibitor/Dopamine Precursor